Cabaletta Bio Inc
CABA2.190USD
+0.010+0.46%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
200.28MValor de mercado
PerdaP/L TTM
Mais detalhes de Cabaletta Bio Inc Empresa
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Informações da empresa
Código da empresaCABA
Nome da EmpresaCabaletta Bio Inc
Data de listagemOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Número de funcionários161
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 25
Endereço2929 Arch Street
CidadePHILADELPHIA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19104
Telefone12677593100
Sitehttps://www.cabalettabio.com/
Código da empresaCABA
Data de listagemOct 25, 2019
CEODr. Steven Nichtberger, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.35M
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Outro
60.29%
Investidores
Investidores
Proporção
Bain Capital Life Sciences Investors, LLC
10.58%
Adage Capital Management, L.P.
9.65%
T. Rowe Price Investment Management, Inc.
7.43%
Jennison Associates LLC
6.58%
Cormorant Asset Management, LP
5.47%
Outro
60.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor
34.02%
Hedge Fund
31.57%
Investment Advisor/Hedge Fund
10.03%
Research Firm
4.01%
Individual Investor
1.65%
Venture Capital
0.11%
Bank and Trust
0.04%
Outro
18.56%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
333
45.33M
50.39%
-18.00M
2025Q1
343
38.78M
72.92%
-24.88M
2024Q4
342
40.39M
82.63%
-20.01M
2024Q3
330
50.24M
102.85%
-12.34M
2024Q2
325
53.21M
110.27%
-11.74M
2024Q1
310
53.11M
110.79%
-5.05M
2023Q4
269
50.62M
118.36%
-623.67K
2023Q3
244
42.61M
108.50%
-4.28M
2023Q2
218
38.30M
97.94%
+637.03K
2023Q1
208
26.57M
91.08%
-5.98M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bain Capital Life Sciences Investors, LLC
2.76M
3.07%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
3.63M
4.04%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.97M
4.41%
-103.98K
-2.55%
Mar 31, 2025
Jennison Associates LLC
2.43M
2.71%
-78.33K
-3.12%
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
3.16%
-23.48K
-0.82%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
